Black Diamond Therapeutics (BDTX) Stock Forecast, Price Target & Predictions
BDTX Stock Forecast
Black Diamond Therapeutics stock forecast is as follows: an average price target of $14.75 (represents a 138.29% upside from BDTX’s last price of $6.19) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
BDTX Price Target
The average price target for Black Diamond Therapeutics (BDTX) is $14.75 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $20.00 to $11.00. This represents a potential 138.29% upside from BDTX's last price of $6.19.
BDTX Analyst Ratings
According to 4 Wall Street analysts, Black Diamond Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for BDTX stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Black Diamond Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 31, 2024 | Laura Prendergast | Raymond James | $20.00 | $5.91 | 238.41% | 223.10% |
| Jun 03, 2024 | Joseph Calanzaro | Piper Sandler | $12.00 | $4.78 | 150.84% | 93.86% |
| May 16, 2024 | Robert Burns | H.C. Wainwright | $11.00 | $5.44 | 102.21% | 77.71% |
| Apr 08, 2024 | Robert Driscoll | Wedbush | $16.00 | $5.06 | 216.21% | 158.48% |
| Mar 18, 2024 | Raghuram Selvaraju | H.C. Wainwright | $12.00 | $4.70 | 155.32% | 93.86% |
The latest Black Diamond Therapeutics stock forecast, released on Jul 31, 2024 by Laura Prendergast from Raymond James, set a price target of $20.00, which represents a 238.41% increase from the stock price at the time of the forecast ($5.91), and a 223.10% increase from BDTX last price ($6.19).
Black Diamond Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 5 |
| Avg Price Target | - | $20.00 | $14.20 |
| Last Closing Price | $6.19 | $6.19 | $6.19 |
| Upside/Downside | -100.00% | 223.10% | 129.40% |
In the current month, the average price target of Black Diamond Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Black Diamond Therapeutics's last price of $6.19. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 10, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 30, 2024 | Raymond James | - | Outperform | Initialise |
| Jun 03, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 08, 2024 | Wedbush | Outperform | Outperform | Hold |
| Jun 28, 2023 | H.C. Wainwright | - | Buy | Upgrade |
| Jun 27, 2023 | Wedbush | - | Outperform | Upgrade |
Black Diamond Therapeutics's last stock rating was published by Piper Sandler on Sep 10, 2024. The company gave BDTX a "Overweight" rating, the same as its previous rate.
Black Diamond Therapeutics Financial Forecast
Black Diamond Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Black Diamond Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. BDTX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Black Diamond Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict BDTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Black Diamond Therapeutics's previous annual EBITDA (undefined) of $NaN.
Black Diamond Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-23.63M | $-22.81M | $-21.38M | $-20.59M | $-19.03M | $-18.99M | $-21.34M |
| High Forecast | $-23.63M | $-22.81M | $-21.38M | $-20.59M | $-19.03M | $-15.73M | $-21.34M |
| Low Forecast | $-23.63M | $-22.81M | $-21.38M | $-20.59M | $-19.03M | $-22.24M | $-21.34M |
| Surprise % | - | - | - | - | - | - | - |
Black Diamond Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BDTX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Black Diamond Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Black Diamond Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to BDTX last annual SG&A of $NaN (undefined).
Black Diamond Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.43 | $-0.41 | $-0.39 | $-0.37 | $-0.34 | $-0.34 | $-0.39 |
| High Forecast | $-0.43 | $-0.41 | $-0.39 | $-0.37 | $-0.34 | $-0.29 | $-0.39 |
| Low Forecast | $-0.43 | $-0.41 | $-0.39 | $-0.37 | $-0.34 | $-0.40 | $-0.39 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Black Diamond Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BDTX previous annual EPS of $NaN (undefined).
Black Diamond Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| PASG | Passage Bio | $0.81 | $6.00 | 640.74% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| ADAP | Adaptimmune Therapeutics | $1.11 | $2.83 | 154.95% | Buy |
| BDTX | Black Diamond Therapeutics | $6.19 | $14.75 | 138.29% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
BDTX Forecast FAQ
Is Black Diamond Therapeutics a good buy?
Yes, according to 4 Wall Street analysts, Black Diamond Therapeutics (BDTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of BDTX's total ratings.
What is BDTX's price target?
Black Diamond Therapeutics (BDTX) average price target is $14.75 with a range of $11 to $20, implying a 138.29% from its last price of $6.19. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Black Diamond Therapeutics stock go up soon?
According to Wall Street analysts' prediction for BDTX stock, the company can go up by 138.29% (from the last price of $6.19 to the average price target of $14.75), up by 223.10% based on the highest stock price target, and up by 77.71% based on the lowest stock price target.
Can Black Diamond Therapeutics stock reach $9?
BDTX's average twelve months analyst stock price target of $14.75 supports the claim that Black Diamond Therapeutics can reach $9 in the near future.
What are Black Diamond Therapeutics's analysts' financial forecasts?
Black Diamond Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-59.353M (high $-56.098M, low $-62.608M), average SG&A $0 (high $0, low $0), and average EPS is $-1.076 (high $-1.017, low $-1.135). BDTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-88.403M (high $-88.403M, low $-88.403M), average SG&A $0 (high $0, low $0), and average EPS is $-1.603 (high $-1.603, low $-1.603).